Targeted inactivation of EPS8 using dendrimer-mediated delivery of RNA interference

Quan Yuan, William Andrew Yeudall, Eunmee Lee, Hu Yang

Research output: Contribution to journalArticle

Abstract

We developed polyamidoamine dendrimers conjugated with epidermal growth factor (EGF) for use in receptor-mediated delivery of therapeutics to cancer cells. Here, we demonstrate the utility of this approach to inhibit proliferation and migration of head and neck squamous carcinoma cells through targeting of EPS8, a key regulator of squamous carcinoma growth and motility. Use of EGF-dendrimers to deliver siRNA or shRNA against EPS8 resulted in inhibition of cell growth and reduction in cell motility. Moreover, more profound repression of the target protein was obtained with repeat exposure to the targeting reagent, and was consistent with the altered biological properties. Thus, targeting of EPS8 can be achieved with EGF-conjugated dendrimers delivering EPS8-specific RNAi therapeutics, leading to a reduction in the malignant phenotype of cells.

Original languageEnglish (US)
Pages (from-to)178-181
Number of pages4
JournalInternational Journal of Pharmaceutics
Volume557
DOIs
StatePublished - Feb 25 2019

Fingerprint

Dendrimers
RNA Interference
Epidermal Growth Factor
Small Interfering RNA
Growth
Cell Movement
Squamous Cell Carcinoma
Phenotype
Neoplasms
Proteins
Therapeutics

Keywords

  • Dendrimer
  • EGFR
  • Oral cancer
  • Signal transduction
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Targeted inactivation of EPS8 using dendrimer-mediated delivery of RNA interference. / Yuan, Quan; Yeudall, William Andrew; Lee, Eunmee; Yang, Hu.

In: International Journal of Pharmaceutics, Vol. 557, 25.02.2019, p. 178-181.

Research output: Contribution to journalArticle

@article{75ffdbbf754048bda87a42f7178fb573,
title = "Targeted inactivation of EPS8 using dendrimer-mediated delivery of RNA interference",
abstract = "We developed polyamidoamine dendrimers conjugated with epidermal growth factor (EGF) for use in receptor-mediated delivery of therapeutics to cancer cells. Here, we demonstrate the utility of this approach to inhibit proliferation and migration of head and neck squamous carcinoma cells through targeting of EPS8, a key regulator of squamous carcinoma growth and motility. Use of EGF-dendrimers to deliver siRNA or shRNA against EPS8 resulted in inhibition of cell growth and reduction in cell motility. Moreover, more profound repression of the target protein was obtained with repeat exposure to the targeting reagent, and was consistent with the altered biological properties. Thus, targeting of EPS8 can be achieved with EGF-conjugated dendrimers delivering EPS8-specific RNAi therapeutics, leading to a reduction in the malignant phenotype of cells.",
keywords = "Dendrimer, EGFR, Oral cancer, Signal transduction, Targeted therapy",
author = "Quan Yuan and Yeudall, {William Andrew} and Eunmee Lee and Hu Yang",
year = "2019",
month = "2",
day = "25",
doi = "10.1016/j.ijpharm.2018.12.060",
language = "English (US)",
volume = "557",
pages = "178--181",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",

}

TY - JOUR

T1 - Targeted inactivation of EPS8 using dendrimer-mediated delivery of RNA interference

AU - Yuan, Quan

AU - Yeudall, William Andrew

AU - Lee, Eunmee

AU - Yang, Hu

PY - 2019/2/25

Y1 - 2019/2/25

N2 - We developed polyamidoamine dendrimers conjugated with epidermal growth factor (EGF) for use in receptor-mediated delivery of therapeutics to cancer cells. Here, we demonstrate the utility of this approach to inhibit proliferation and migration of head and neck squamous carcinoma cells through targeting of EPS8, a key regulator of squamous carcinoma growth and motility. Use of EGF-dendrimers to deliver siRNA or shRNA against EPS8 resulted in inhibition of cell growth and reduction in cell motility. Moreover, more profound repression of the target protein was obtained with repeat exposure to the targeting reagent, and was consistent with the altered biological properties. Thus, targeting of EPS8 can be achieved with EGF-conjugated dendrimers delivering EPS8-specific RNAi therapeutics, leading to a reduction in the malignant phenotype of cells.

AB - We developed polyamidoamine dendrimers conjugated with epidermal growth factor (EGF) for use in receptor-mediated delivery of therapeutics to cancer cells. Here, we demonstrate the utility of this approach to inhibit proliferation and migration of head and neck squamous carcinoma cells through targeting of EPS8, a key regulator of squamous carcinoma growth and motility. Use of EGF-dendrimers to deliver siRNA or shRNA against EPS8 resulted in inhibition of cell growth and reduction in cell motility. Moreover, more profound repression of the target protein was obtained with repeat exposure to the targeting reagent, and was consistent with the altered biological properties. Thus, targeting of EPS8 can be achieved with EGF-conjugated dendrimers delivering EPS8-specific RNAi therapeutics, leading to a reduction in the malignant phenotype of cells.

KW - Dendrimer

KW - EGFR

KW - Oral cancer

KW - Signal transduction

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85059532457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059532457&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2018.12.060

DO - 10.1016/j.ijpharm.2018.12.060

M3 - Article

VL - 557

SP - 178

EP - 181

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

ER -